BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38581966)

  • 1. Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors.
    Mansour MA; Hassan GS; Serya RAT; Jaballah MY; Abouzid KAM
    Bioorg Chem; 2024 Jun; 147():107332. PubMed ID: 38581966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors.
    Arai M; Hanada M; Moriyama H; Ohmoto H; Miyake T; Naka K; Sawa M
    Bioorg Med Chem Lett; 2024 Aug; 108():129797. PubMed ID: 38759932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
    Tan B; Zhang X; Quan X; Zheng G; Li X; Zhao L; Li W; Li B
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127339. PubMed ID: 32631540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor.
    Wang Y; Liu Y; Zhang Y; Zhang Z; Xu L; Wang J; Yang Y; Hu B; Yao Y; Wei M; Wang J; Tang B; Zhang K; Liu S; Yang G
    Eur J Med Chem; 2024 May; 271():116395. PubMed ID: 38626523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors.
    Wang Z; Zhang Y; Wang H; Wang X; Yu Z; Zhao L
    Bioorg Med Chem Lett; 2022 Apr; 61():128552. PubMed ID: 35051574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1
    Park MS; Park HJ; An YJ; Choi JH; Cha G; Lee HJ; Park SJ; Dewang PM; Kim DK
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):702-712. PubMed ID: 32164459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
    Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
    Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
    Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
    Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
    Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
    J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology.
    Ling LE; Lee WC
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2190-202. PubMed ID: 21619541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
    Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
    Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
    Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
    Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
    Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
    Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK5 signaling pathway mediates neurogenesis and functional recovery after cerebral ischemia/reperfusion in rats via Gadd45b.
    Zhang K; Zhang Q; Deng J; Li J; Li J; Wen L; Ma J; Li C
    Cell Death Dis; 2019 May; 10(5):360. PubMed ID: 31043581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
    Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
    Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5.
    Hanke T; Wong JF; Berger BT; Abdi I; Berger LM; Tesch R; Tredup C; Bullock AN; Müller S; Knapp S
    ACS Chem Biol; 2020 Apr; 15(4):862-870. PubMed ID: 32176847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
    J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.